[EN] BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS<br/>[FR] COMPOSÉS BICYCLIQUES EN TANT QU'INHIBITEURS DE MPGES-1
申请人:GLENMARK PHARMACEUTICALS SA
公开号:WO2013118071A1
公开(公告)日:2013-08-15
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (m PGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.
BICYCLIC COMPOUNDS AS mPGES-1 INHIBITORS
申请人:Glenmark Pharmaceuticals S.A.
公开号:US20130210844A1
公开(公告)日:2013-08-15
The present disclosure is directed to compounds of formula (I), and pharmaceutically acceptable salts thereof, as mPGES-1 inhibitors. These compounds are inhibitors of the microsomal prostaglandin E synthase-1 (mPGES-1) enzyme and are therefore useful in the treatment of pain and/or inflammation from a variety of diseases or conditions, such as asthma, osteoarthritis, rheumatoid arthritis, acute or chronic pain and neurodegenerative diseases.